Document Detail


Current management and perspectives for HCV recurrence after liver transplantation.
MedLine Citation:
PMID:  23286847     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Hepatitis C virus (HCV) infection is one of the leading causes of end-stage liver disease and the main indication for liver transplantation (LT) in most countries. All patients who undergo LT with detectable serum HCV RNA experience graft reinfection. Between 20 and 30% of patients develop cirrhosis within 5 years post-LT. The outcome of transplant patients with cirrhosis on the graft is severe, with a rate of decompensation at 1 year of around 40%. To date, retransplantation is the only option for patients who develop decompensation. Until 2011, standard antiviral therapy, using pegylated interferon (PEG-IFN) and ribavirin (RBV), was the only effective therapy. Obtaining a sustained virological response (SVR) in the setting of LT greatly improves overall and graft survival, but this only concerns 30% of transplanted patients. Direct-acting antivirals (DAA) such as protease inhibitors, polymerase or other non-structural proteins inhibitors represent a new era in HCV-associated liver disease. Although their use in the field of liver transplantation seems to be essential, there are some limitations due to safety and tolerance. One limitation is the potential interaction with calcineurin inhibitors. We describe the preliminary results of triple therapy with boceprevir or telaprevir in terms of efficacy and safety in liver transplant recipients.
Authors:
Audrey Coilly; Bruno Roche; Didier Samuel
Related Documents :
2688207 - Prediction of early kidney transplant rejection by a crossmatch with donor skin.
6380417 - Cutaneous nonpulmonary mycobacterium chelonei infection. successful treatment with sulf...
24290247 - Clinical and histological outcomes following living-related liver transplantation in ch...
24691417 - Role of myeloid-derived suppressor cells in mouse pre-sensitized cardiac transplant model.
1097167 - Ultrasound in the diagnosis of fluid collections following renal transplantation.
19376387 - Pancreas-kidney transplantation and the evolution of pancreatic autoantibodies.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Liver international : official journal of the International Association for the Study of the Liver     Volume:  33 Suppl 1     ISSN:  1478-3231     ISO Abbreviation:  Liver Int.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160857     Medline TA:  Liver Int     Country:  United States    
Other Details:
Languages:  eng     Pagination:  56-62     Citation Subset:  IM    
Copyright Information:
© 2012 John Wiley & Sons A/S.
Affiliation:
AP-HP Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France; UMR-S 785, Univ Paris-Sud, Villejuif, France; Inserm, Unit 785, Villejuif, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  How to optimize HCV therapy in genotype 1 patients with cirrhosis.
Next Document:  HCV therapy in HIV-infected patients.